{
    "clinical_study": {
        "@rank": "67078", 
        "arm_group": [
            {
                "arm_group_label": "B", 
                "arm_group_type": "No Intervention", 
                "description": "After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will only regularly follow up."
            }, 
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will receive 2-3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) treatment (every 4 weeks)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of dendritic and cytokine-induced\n      killer cells (DC-CIK) for colorectal cancer (CRC)."
        }, 
        "brief_title": "Study of DC-CIK to Treat Colorectal Cancer", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "60 patients with stage \u2162 CRC, who had received neoadjuvant and (or) adjuvant chemotherapy or\n      (and) radiotherapy according to NCCN guidelines, and got complete response (CR), will be\n      randomly divided into group A (receive DC-CIK treatment) or group B (just regularly follow\n      up), and the randomize ratio will be 1:1. Patients in group A will receive 2-3 cycles of\n      DC-CIK cells treatment (every 4 weeks). Patients in group B will have no anti-tumor therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female patients \u2265 18 years of age;\n\n          2. CRC with histological diagnose, and had received neoadjuvant and (or) adjuvant\n             chemotherapy or (and) radiotherapy and got complete response (CR) with imaging;\n\n          3. Patients who have a life expectancy of at least 3 months;\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1;\n\n          5. The bone marrow functioned normally (WBC > 4.0\u00d7109/L, Hb > 120 g/L, PLT > 100\u00d7109/L);\n\n          6. The ECG results were normal, and the liver and kidney were functional.\n\n        Exclusion Criteria:\n\n          1. Patients who had distant metastases;\n\n          2. Patients with uncontrolled infection; underlying disease that was severe or\n             life-threatening;\n\n          3. Patients who were pregnant or lactating;\n\n          4. ECOG perform status \u2265 2;\n\n          5. Patients who are suffering from auto immune diseases or patients who need to accept\n             glucocorticoid treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839539", 
            "org_study_id": "CRC-01"
        }, 
        "intervention": {
            "arm_group_label": "A", 
            "intervention_name": "dendritic and cytokine-induced killer cells", 
            "intervention_type": "Biological", 
            "other_name": "DC-CIK"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "colorectal cancer", 
            "DC-CIK", 
            "CRC"
        ], 
        "lastchanged_date": "April 22, 2013", 
        "location": {
            "contact": {
                "last_name": "Hanfeng Liu", 
                "phone": "86-771-3277289"
            }, 
            "facility": {
                "address": {
                    "city": "Nanning", 
                    "country": "China", 
                    "state": "Guangxi", 
                    "zip": "530000"
                }, 
                "name": "Guangxi Medical University"
            }, 
            "investigator": {
                "last_name": "Hanfeng Liu", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase \u2161 Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Stage \u2162 Colorectal Cancer", 
        "overall_contact": {
            "last_name": "Hanfeng Liu", 
            "phone": "86-771-3277289"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839539"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guangxi Medical University", 
            "investigator_full_name": "Weiliang Sun", 
            "investigator_title": "Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Quality of life (QOL)", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Laboratory findings (The number of CD3+ (or CD8+ or CD4+ or CD56+)T cell)", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "source": "Guangxi Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangxi Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}